These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1841754

  • 1. Mechanism based chemotherapy for prostate cancer.
    Sheridan VR, Tew KD.
    Cancer Surv; 1991; 11():239-54. PubMed ID: 1841754
    [Abstract] [Full Text] [Related]

  • 2. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ, Smith DC.
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [Abstract] [Full Text] [Related]

  • 3. Estramustine-based chemotherapy.
    Hudes G.
    Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
    Naik H, Lehr JE, Pienta KJ.
    Urology; 1996 Sep; 48(3):508-11. PubMed ID: 8804514
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
    Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R.
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
    [Abstract] [Full Text] [Related]

  • 6. Estramustine depolymerizes microtubules by binding to tubulin.
    Dahllöf B, Billström A, Cabral F, Hartley-Asp B.
    Cancer Res; 1993 Oct 01; 53(19):4573-81. PubMed ID: 8402630
    [Abstract] [Full Text] [Related]

  • 7. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate.
    Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC.
    Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618
    [Abstract] [Full Text] [Related]

  • 8. Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine.
    Wang M, Tew KD, Stearns ME.
    Anticancer Res; 1987 Jun 15; 7(6):1165-71. PubMed ID: 3327449
    [Abstract] [Full Text] [Related]

  • 9. Effects of microtubule inhibitors-taxol, vinblastine and estramustine on the growth and p53 gene expression in the hormone independent human prostatic JCA-1 cells.
    Darby E, An S, Ng C, Hsieh TC, Mallouh C, Wu JM.
    Anticancer Res; 1996 Jun 15; 16(6B):3647-52. PubMed ID: 9042236
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
    Smith DC, Chay CH, Dunn RL, Fardig J, Esper P, Olson K, Pienta KJ.
    Cancer; 2003 Jul 15; 98(2):269-76. PubMed ID: 12872344
    [Abstract] [Full Text] [Related]

  • 13. [Pharmacology and metabolism of a new therapeutic drug for prostatic cancer "Estracyt"].
    Yamanaka H, Shida K.
    Gan To Kagaku Ryoho; 1984 Mar 15; 11(3):537-44. PubMed ID: 6422861
    [Abstract] [Full Text] [Related]

  • 14. Effect of estramustine phosphate on the assembly of isolated bovine brain microtubules and fast axonal transport in the frog sciatic nerve.
    Kanje M, Deinum J, Wallin M, Ekström P, Edström A, Hartley-Asp B.
    Cancer Res; 1985 May 15; 45(5):2234-9. PubMed ID: 2580617
    [Abstract] [Full Text] [Related]

  • 15. Intracellular effects of estramustine (Estracyt/Emcyt).
    Tew KD, Stearns ME.
    Prog Clin Biol Res; 1989 May 15; 303():169-75. PubMed ID: 2674983
    [No Abstract] [Full Text] [Related]

  • 16. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer.
    Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC.
    Urology; 1997 Sep 15; 50(3):401-6; discussion 406-7. PubMed ID: 9301705
    [Abstract] [Full Text] [Related]

  • 17. Kinetic stabilization of microtubule dynamics by estramustine is associated with tubulin acetylation, spindle abnormalities, and mitotic arrest.
    Mohan R, Panda D.
    Cancer Res; 2008 Aug 01; 68(15):6181-9. PubMed ID: 18676841
    [Abstract] [Full Text] [Related]

  • 18. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK.
    Cancer J; 2007 Aug 01; 13(2):125-9. PubMed ID: 17476141
    [Abstract] [Full Text] [Related]

  • 19. The effects of estramustine on metaphase and anaphase in DU 145 prostatic carcinoma cells.
    Sheridan VR, Speicher LA, Tew KD.
    Eur J Cell Biol; 1991 Apr 01; 54(2):268-76. PubMed ID: 1879438
    [Abstract] [Full Text] [Related]

  • 20. Antimicrotubule effects of estramustine, an antiprostatic tumor drug.
    Stearns ME, Tew KD.
    Cancer Res; 1985 Aug 01; 45(8):3891-7. PubMed ID: 4016756
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.